Uncertainties in Evaluating Patient and Caregiver Health-Related Quality of Life and Disease Burden in NICE HST Submissions

Author(s)

Looby A1, Dymond A1, Green W1, Malottki K2, Wentzel H3
1York Health Economics Consortium, York, NYK, UK, 2Sanofi, Reading, RDG, UK, 3Sanofi, Reading, LON, UK

OBJECTIVES: To review NICE (National Institute for Health and Care Excellence) HST (Highly Specialised Technology) appraisals and determine the most commonly reported uncertainties relating to health-related quality of life (HRQoL) and disease burden for patients & caregivers when modelling rare diseases.

METHODS: The company submissions for 24 HST appraisals were reviewed to investigate the methods used to capture patient & caregiver HRQoL and disease burden, and identify key areas of uncertainty. The evidence review group (ERG) and committee meeting reports were reviewed to determine common criticisms and elements influencing the committee decisions.

RESULTS: Companies seldom used the EQ-5D collected in disease-specific clinical studies (recommended by NICE) to estimate patient & caregiver HRQoL, citing biases with single-arm studies, small patient numbers and limited sensitivity of generic measures in rare diseases. Vignette studies were considered acceptable alternatives if validated by clinicians and completed by the patient. Utility values from proxy conditions were also considered appropriate if sufficient evidence was provided to display similarities between disease characteristics and symptoms. Approximately 70% of submissions reviewed quantified caregiver disutility but concerns around the methods adopted were frequently reported by ERGs and committees (e.g. the inappropriate inclusion of bereavement disutilities). The quantification of patient and caregiver burden was deemed acceptable if presented as separate scenario analysis. However, companies were often criticised for overestimating productivity loss when using the human capital approach, rather than the friction cost method.

CONCLUSIONS: All technologies from fully completed submissions were recommended in some capacity by NICE (e.g. accompanying managed access agreement) thereby indicating that committees are understanding of the substantial uncertainties associated with modelling patient and caregiver HRQoL and disease burden in rare diseases. Nevertheless, common themes were identified that may influence the approach adopted for future appraisals (e.g. appropriate methodology for vignette studies and proxy utilities).

Conference/Value in Health Info

2022-11, ISPOR Europe 2022, Vienna, Austria

Value in Health, Volume 25, Issue 12S (December 2022)

Code

PCR134

Topic

Health Technology Assessment, Patient-Centered Research

Topic Subcategory

Patient-reported Outcomes & Quality of Life Outcomes, Value Frameworks & Dossier Format

Disease

No Additional Disease & Conditions/Specialized Treatment Areas

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×